地西他滨联合预激方案治疗中高危骨髓增生异常综合征的疗效  

Efficacy of Decitabine Combined with Pre-excitation Regimen in the Treatment of Middle and High-Risk Myelodysplastic Syndrome

作　　者：张芳芳 ZHANG Fang-fang(Department of Hematology,Pingdingshan First People's Hospital,Pingdingshan 467000,Henan Province,China)

机构地区：[1]平顶山市第一人民医院血液内科,河南平顶山467000

出　　处：《罕少疾病杂志》2022年第4期93-95,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探究地西他滨(DAC)联合预激方案对中高危骨髓增生异常综合征(MDS)患者的治疗效果。方法选取2017年1月至2019年2月在本院接受治疗的MDS患者66例,采用随机数表法分为观察组和对照组,分别有患者34例、32例。其中观察组患者采用DAC联合预激方案治疗,对照组患者仅采用预激方案治疗。观察两组的治疗效果、生存情况,血清铁蛋白、维生素B2、叶酸浓度以及不良反应发生情况,治疗总有效率、并发症、死亡率行χ^(2)检验,两组中位生存期、血清铁蛋白、维生素B2、叶酸浓度差异行独立、配对t检验。结果观察组治疗总有效率为62.50%,高于对照组(34.38%,P<0.05);观察组患者的死亡人数为9例(26.47%),小于对照组[16例(50.00%),P<0.05];观察组患者的中位生存期为(16.38±3.82)个月,对照组为(11.00±4.72)个月,前者较长(P<0.05);治疗后,两组患者的铁蛋白、维生素B2、叶酸浓度均降低(P<0.05),且观察组治疗后的上述参数评分均低于对照组(P<0.05)。结论DAC联合预激方案治疗能够有效缓解MDS患者症状,提高患者的生存几率、延长患者生存时间,抑制细胞的恶性繁殖,对MDS患者的治疗效果显著,值得在临床治疗中推广。Objective To explore the therapeutic effects and safety of decitabine(DAC)combined with pre-excitation regimen in patients with middle and high-risk myelodysplastic syndrome(MDS).Methods A total of 66 patients with MDS treated in the hospital from January 2017 to February 2019 were selected and divided into observation group(34 cases)and control group(32 cases)by random number table method.The observation group were treated with DAC and pre-excitation regimen,while the control group were treated with pre-excitation regimen alone.The therapeutic effects,survival,serum ferritin,vitamin B2,folic acid concentration,and occurrence of adverse reactions in the two groups were observed.The total effective rate of treatment,complications,and mortality were enrolled in chi-square test,while the differences in median survival time,serum ferritin,vitamin B2 and folic acid concentration were enrolled in independent and paired t test.Results The total effective rate of treatment in the observation group was 62.50%,higher than 34.38%in the control group(P<0.05).The number of deaths in the observation group was 9(26.47%),smaller than the 16(50.00%)in the control group(P<0.05).The median survival time of the observation group was(16.38±3.82)months,longer than(11.00±4.72)of the control group(P<0.05).After treatment,the concentrations of ferritin,vitamin B2,and folic acid were reduced in the two groups(P<0.05),which were lower in the observation group than in the control group(P<0.05).Conclusion DAC combined with pre-excitation regimen can effectively alleviate the symptoms in patients with MDS,improve their survival rate,prolong their survival time,and inhibit malignant growth of cells.Besides,it has a significant therapeutic effect on MDS.It is worthy of promotion in clinical treatment.

关 键 词：地西他滨 中高危骨髓增生异常综合征 安全性 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R979.1[医药卫生—内科学]